Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,770,000 shares, a growth of 6.6% from the December 31st total of 1,660,000 shares. Currently, 11.3% of the company's shares are short sold. Based on an average daily trading volume, of 316,200 shares, the days-to-cover ratio is presently 5.6 days.

Analysts Set New Price Targets

A number of research firms have recently commented on IRON. Raymond James upgraded Disc Medicine from an "outperform" rating to a "strong-buy" rating and raised their price objective for the stock from $66.00 to $110.00 in a report on Monday, November 4th. HC Wainwright restated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Wedbush reiterated an "outperform" rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley upgraded Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price objective on the stock in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus increased their target price on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Disc Medicine presently has an average rating of "Buy" and a consensus target price of $88.90.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON traded down $1.47 during trading on Friday, hitting $54.82. The company's stock had a trading volume of 356,954 shares, compared to its average volume of 447,302. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The stock's 50-day moving average price is $61.15 and its two-hundred day moving average price is $54.38. The company has a market capitalization of $1.63 billion, a PE ratio of -13.77 and a beta of 0.74.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15. On average, equities analysts predict that Disc Medicine will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 12,791 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the transaction, the chief executive officer now owns 72,065 shares of the company's stock, valued at $4,757,010.65. This trade represents a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William Richard White sold 1,957 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $64.63, for a total transaction of $126,480.91. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,921 shares of company stock worth $5,389,978. 4.24% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new stake in shares of Disc Medicine in the 2nd quarter valued at about $554,000. The Manufacturers Life Insurance Company raised its stake in Disc Medicine by 26.7% during the second quarter. The Manufacturers Life Insurance Company now owns 28,294 shares of the company's stock valued at $1,275,000 after buying an additional 5,960 shares in the last quarter. Algert Global LLC bought a new position in Disc Medicine during the 2nd quarter worth approximately $239,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Disc Medicine in the 2nd quarter worth approximately $636,000. Finally, SG Americas Securities LLC grew its position in shares of Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after acquiring an additional 793 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.